TY - JOUR
T1 - A naphthoquinone derivative can induce anemia through phosphatidylserine exposure-mediated erythrophagocytosis
AU - Noh, Ji Yoon
AU - Park, Jong Sook
AU - Lim, Kyung Min
AU - Kim, Keunyoung
AU - Bae, Ok Nam
AU - Chung, Seung Min
AU - Shin, Sue
AU - Chung, Jin Ho
PY - 2010/5
Y1 - 2010/5
N2 - A naphthoquinone derivative, β-lapachone (βL; 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione), is receiving huge attention for its potent therapeutic effects against various diseases. However, during the preclinical safety evaluation, repeated oral treatment of βL in rats induced anemia, i.e., a significantly decreased erythrocyte count. In this study, in an effort to elucidate the mechanism underlying the βL-induced anemia, we investigated the effects of βL on erythrocytes with freshly isolated human erythrocytes in vitro and rat in vivo. βL did not induce erythrocyte hemolysis, indicating that direct hemotoxicity was not involved in βL-associated anemia. Meanwhile, phosphatidylserine (PS) exposure along with spherocytic shape change and microvesicle generation, important factors in the facilitation of erythrophagocytosis, were increased significantly by βL. The PS exposure on erythrocytes was from βL-induced reactive oxygen species generation and subsequent depletion of reduced glutathione and protein thiol, which culminated in the modified activities of phospholipid translocases, i.e., inhibition of flippase and activation of scramblase. It is important to note that coincubation of macrophage with βL-treated erythrocyte in vitro showed increased erythrophagocytosis, demonstrating that the removal of erythrocyte by macrophage can be facilitated by βL-induced PS exposure. In good accordance with these in vitro results, after oral administration of βL in rats, increased PS exposure and depletion of glutathione were observed along with enhanced splenic sequestration of erythrocytes. In conclusion, these results suggest that βL-induced anemia might be mediated through the PS exposure and subsequent erythrophagocytosis, providing novel insight into the drug-induced anemia.
AB - A naphthoquinone derivative, β-lapachone (βL; 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione), is receiving huge attention for its potent therapeutic effects against various diseases. However, during the preclinical safety evaluation, repeated oral treatment of βL in rats induced anemia, i.e., a significantly decreased erythrocyte count. In this study, in an effort to elucidate the mechanism underlying the βL-induced anemia, we investigated the effects of βL on erythrocytes with freshly isolated human erythrocytes in vitro and rat in vivo. βL did not induce erythrocyte hemolysis, indicating that direct hemotoxicity was not involved in βL-associated anemia. Meanwhile, phosphatidylserine (PS) exposure along with spherocytic shape change and microvesicle generation, important factors in the facilitation of erythrophagocytosis, were increased significantly by βL. The PS exposure on erythrocytes was from βL-induced reactive oxygen species generation and subsequent depletion of reduced glutathione and protein thiol, which culminated in the modified activities of phospholipid translocases, i.e., inhibition of flippase and activation of scramblase. It is important to note that coincubation of macrophage with βL-treated erythrocyte in vitro showed increased erythrophagocytosis, demonstrating that the removal of erythrocyte by macrophage can be facilitated by βL-induced PS exposure. In good accordance with these in vitro results, after oral administration of βL in rats, increased PS exposure and depletion of glutathione were observed along with enhanced splenic sequestration of erythrocytes. In conclusion, these results suggest that βL-induced anemia might be mediated through the PS exposure and subsequent erythrophagocytosis, providing novel insight into the drug-induced anemia.
UR - http://www.scopus.com/inward/record.url?scp=77951062025&partnerID=8YFLogxK
U2 - 10.1124/jpet.109.164608
DO - 10.1124/jpet.109.164608
M3 - Article
C2 - 20164298
AN - SCOPUS:77951062025
SN - 0022-3565
VL - 333
SP - 414
EP - 420
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 2
ER -